Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia.

Saved in:
Bibliographic Details
Title: Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia.
Authors: Ramos-Muntada M; Cell Biology, Physiology and Immunology Department, Genetics of Male Fertility Group, Universitat Autònoma de Barcelona, Spain., Trincado JL; Department of Biomedicine, School of Medicine, Josep Carreras Leukemia Research Institute, University of Barcelona, Spain.; CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Spain.; Red Española de Terápias Avanzadas (TERAV), ISCIII, Barcelona, Spain., Blanco J; Cell Biology, Physiology and Immunology Department, Genetics of Male Fertility Group, Universitat Autònoma de Barcelona, Spain., Bueno C; Department of Biomedicine, School of Medicine, Josep Carreras Leukemia Research Institute, University of Barcelona, Spain.; Red Española de Terápias Avanzadas (TERAV), ISCIII, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), ISCIII, Barcelona, Spain., Rodríguez-Cortez VC; Department of Biomedicine, School of Medicine, Josep Carreras Leukemia Research Institute, University of Barcelona, Spain.; Red Española de Terápias Avanzadas (TERAV), ISCIII, Barcelona, Spain., Bataller A; Department of Biomedicine, School of Medicine, Josep Carreras Leukemia Research Institute, University of Barcelona, Spain.; Red Española de Terápias Avanzadas (TERAV), ISCIII, Barcelona, Spain.; Hematology Department, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Spain., López-Millán B; Department of Biomedicine, School of Medicine, Josep Carreras Leukemia Research Institute, University of Barcelona, Spain.; Red Española de Terápias Avanzadas (TERAV), ISCIII, Barcelona, Spain., Schwab C; Wolfson Childhood Cancer Research Centre, Newcastle University, UK., Ortega M; Hematology Service, Experimental Hematology, Vall d'Hebrón Institute of Oncology (VHIO), Vall d'Hebrón Hospital Universitari, Barcelona, Spain., Velasco P; Pediatric Oncology and Hematology Department, Vall d'Hebrón Hospital, Barcelona, Spain., Blanco ML; Hematology Laboratory, Hospital Sant Pau, Barcelona, Spain., Nomdedeu J; Hematology Laboratory, Hospital Sant Pau, Barcelona, Spain., Ramírez-Orellana M; Hematology Diagnostic Laboratory, Hospital Niño Jesús, Madrid, Spain., Minguela A; Immunology Service, Clinic University Hospital Virgen de la Arrixaca and Instituto Murciano de Investigación Biomédica (IMIB), Murcia, Spain., Fuster JL; Pediatric Hematology and Oncology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain., Cuatrecasas E; Hematology Laboratory, Institut de Recerca Hospital Sant Joan de Déu, Barcelona, Spain., Camós M; Hematology Laboratory, Hospital Sant Joan de Déu, University of Barcelona, Spain.; Leukemia and Other Pediatric Hemopathies, Developmental Tumor Biology Group, Institut de Recerca Hospital Sant Joan de Déu Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain., Ballerini P; AP-HP, Service d'Hématologie Pédiatrique, Hôpital A. Trousseau, Paris, France., Escherich G; Department of Pediatric Hematology and Oncology, University Medical Center Hamburg, Germany., Boer J; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., DenBoer M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Department of Pediatric Oncology/Hematology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands., Hernández-Rivas JM; Departamento de Hematología, Salamanca-IBSAL, Hospital Universitario de Salamanca, Spain., Calasanz MJ; CIMA Lab Diagnostics, Universidad de Navarra, Pamplona, Spain., Cazzaniga G; Fondazione Tettamanti, Monza, Italy., Harrison CJ; Wolfson Childhood Cancer Research Centre, Newcastle University, UK., Menéndez P; Department of Biomedicine, School of Medicine, Josep Carreras Leukemia Research Institute, University of Barcelona, Spain.; Red Española de Terápias Avanzadas (TERAV), ISCIII, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), ISCIII, Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain., Molina O; Department of Biomedicine, School of Medicine, Josep Carreras Leukemia Research Institute, University of Barcelona, Spain.; Red Española de Terápias Avanzadas (TERAV), ISCIII, Barcelona, Spain.
Source: Molecular oncology [Mol Oncol] 2022 Aug; Vol. 16 (16), pp. 2899-2919. Date of Electronic Publication: 2022 Jul 19.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1878-0261
DOI:10.1002/1878-0261.13276